Showing posts with label Swenerton. Show all posts
Showing posts with label Swenerton. Show all posts
Friday, April 20, 2012
Medscape: (Avastin) Bevacizumab: First-Line Therapy in Ovarian Cancer?: Evidence for First-Line Therapy Dr's Markman, Burger, Swenterton
Bevacizumab: First-Line Therapy in Ovarian Cancer?: Evidence for First-Line Therapy
Editor’s Note:
Two phase 3 trials published in the New England Journal of Medicine on December 29, 2011, found bevacizumab to be active as first-line therapy in advanced ovarian cancer. Although both trials showed an increase in progression-free survival [PFS], not enough time has elapsed to determine whether the drug extends overall survival. Furthermore, it is unclear whether bevacizumab in ovarian cancer is best used as first-line or second-line therapy. Recently, Drs. Robert Burger and Kenneth Swenerton participated in a Medscape virtual debate via email to address this question: "Should bevacizumab be used as first-line therapy in patients with advanced ovarian cancer?" Dr. Maurie Markman served as moderator. What follows is their conversation......
add your opinions
Avastin
,
Bevacizumab
,
burger
,
first line therapy
,
markman
,
Swenerton
Subscribe to:
Posts
(
Atom
)